Ardelyx announces successful phase III trial of tenapanor for hyperphosphatemia

Thursday, February 16, 2017

Ardelyx, a clinical-stage company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, has reported that the phase III clinical trial evaluating the efficacy and safety of tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis met its primary endpoint and was generally well-tolerated.

[Read More]

Ardelyx licenses phosphate inhibitor program to Sanofi in $198M deal

Wednesday, February 26, 2014

Ardelyx, a venture-funded biopharmaceutical company, has licensed to Sanofi its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2). Ardelyx will receive an undisclosed upfront payment from Sanofi. Total development and regulatory milestones could potentially reach up to $198 million. Ardelyx also would be entitled to royalties on product sales. In addition, Ardelyx retains an option to participate in co-promotional activities for the U.S. market.

[Read More]